Bioresorbable Coronary Stents Market Size, Share & Trends Analysis Report By Material (Polymer, Metal), By Drug (Sirolimus, Novalimus), By End Use (Outpatient, Inpatient Facilities), By Region, And Segment Forecasts, 2025 - 2030

Bioresorbable Coronary Stents Market Size, Share & Trends Analysis Report By Material (Polymer, Metal), By Drug (Sirolimus, Novalimus), By End Use (Outpatient, Inpatient Facilities), By Region, And Segment Forecasts, 2025 - 2030


Bioresorbable Coronary Stents Market Growth & Trends

The global bioresorbable coronary stents market size is expected to reach USD 210.1 million by 2030, expanding at a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. better device attributes of second-generation coronary stents will provide the ascending push to this market.

Bioresorbable stents are intended majorly for the young adult population, whereby these individuals are enabled with a normal functioning artery following complete resorption of the dissolvable devices.Lifestyle diseases and prevalence of associated risk factors underpin the growth in atherosclerosis-related cardiac events. This drives the global disease prevalence in young adults as well as the high volume of elective Percutaneous Coronary Interventions (PCI).

What sets the second-generation bioresorbable coronary stents apart? - Learning from past mistakes, manufacturers have developed new generation bioresorbable with thinner strut thicknesses, faster resorption times, and better radial force. Amaranth, with a single-minded focus on strut thickness, has developed three such devices. Each with a thinner strut. The latest, Magnitude boasts of 100 microns.

Another factor providing a fillip to this market is the less-invasive nature of PCIs as compared to coronary artery bypass grafting, resulting in their high elective procedure volume. In most parts of the world, lack of auditing to check inappropriate surgeries drives the number of coronary stenting procedures. Hence, this market is expected to witness growth due to the high volume of elective PCI, particularly in APAC and Europe.

Bioresorbable Coronary Stents Market Report Highlights
  • The polymer segment held the largest market share of 50.2% in 2024 and the metal segment is anticipated to grow at the fastest CAGR over the forecast period.
  • The sirolimus segment held the largest market share of 63.1% in 2024 and the Novalimus segment is anticipated to grow at the fastest CAGR from 2025 to 2030.
  • The outpatient facilities segment held the largest market share of 61.9% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
  • Strategic efforts undertaken by the companies to gain a higher market share center on bioresorbable coronary stents development. Companies targeting the clinical pipeline have developed second-generation bioresorbable products with better design specifications, such as devices with thinner strut thicknesses and faster absorption rates that gain comparability with the gold standard, drug-eluting metallic stents.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Material
1.2.2. Drug
1.2.3. End use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Material outlook
2.2.2. Drug outlook
2.2.3. End use outlook
2.3. Competitive Insights
Chapter 3. Bioresorbable Coronary Stents Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Development in biocompatible materials
3.2.1.2. Rising incidence of cardiovascular diseases
3.2.1.3. Advancements in minimally invasive procedures
3.2.2. Market restraint analysis
3.2.2.1. High initial cost
3.2.2.2. Material recalls
3.3. Bioresorbable Coronary Stents Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
Chapter 4. Bioresorbable Coronary Stents Market: Material Estimates & Trend Analysis
4.1. Global Bioresorbable Coronary Stents Market: Material Dashboard
4.2. Global Bioresorbable Coronary Stents Market: Material Movement Analysis
4.3. Global Bioresorbable Coronary Stents Market by Material, Revenue
4.4. Polymer
4.4.1. Polymer market estimates and forecasts 2018 to 2030 (USD Billion)
4.5. Metal
4.5.1. Metal market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. Bioresorbable Coronary Stents Market: Drug Estimates & Trend Analysis
5.1. Global Bioresorbable Coronary Stents Market: Drug Dashboard
5.2. Global Bioresorbable Coronary Stents Market: Drug Movement Analysis
5.3. Global Bioresorbable Coronary Stents Market by Drug, Revenue
5.4. Sirolimus
5.4.1. Sirolimus market estimates and forecasts 2018 to 2030 (USD Billion)
5.5. Novalimus
5.5.1. Novalimus market estimates and forecasts 2018 to 2030 (USD Billion)
5.6. Others
5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 6. Bioresorbable Coronary Stents Market: End Use Estimates & Trend Analysis
6.1. Global Bioresorbable Coronary Stents Market: End Use Dashboard
6.2. Global Bioresorbable Coronary Stents Market: End Use Movement Analysis
6.3. Global Bioresorbable Coronary Stents Market by End Use, Revenue
6.4. Inpatient Facilities
6.4.1. Inpatient facilities market estimates and forecasts 2018 to 2030 (USD Billion)
6.5. Outpatient Facilities
6.5.1. Outpatient facilities market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 7. Bioresorbable Coronary Stents Market: Regional Estimates & Trend Analysis by Country, Material, Drug and End Use
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Manufacturers
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company market share analysis, 2024
8.4. Company Profiles
8.4.1. Biotronik
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Material benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Meril Life Sciences Pvt. Ltd.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Material benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Elixir Medical
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Material benchmarking
8.4.3.4. Strategic initiatives
8.4.4. REVA Medical, LLC
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Material benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Arterial Remodeling Technologies SA
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Material benchmarking
8.4.5.4. Strategic initiatives
8.4.6. LifeTech Scientific
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Material benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Microport Scientific Corporation
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Material benchmarking
8.4.7.4. Strategic initiatives
8.4.8. LEPU Medical
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Material benchmarking
8.4.8.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings